Skip to main content
TipRanks
Go Ultimate75% OFF

CytomX Therapeutics (6C1) Q3 2026 Earnings Report

6 Followers

DE:6C1 Q3 2026 EPS Results

Actual EPS
-EUR 0.08
Consensus EPS
-EUR 0.06
Beat/Miss
Missed by -EUR 0.02
One Year Ago EPS
-EUR 0.08

DE:6C1 Q3 2026 Revenue Results

Actual Revenue
EUR 1.52M
Expected Revenue
EUR 9.35M
Beat/Miss
Missed by -EUR 7.83M
YoY Revenue Growth
-71.69%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/05/2026
Time
After Close
Conference Call
Thursday, November 5, 2026
DE:6C1 Upcoming Earnings

CytomX Therapeutics's next earnings date is estimated for February 24, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:6C1 Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 05, 2026|% Change Since:-11.89%|
Earnings Call Sentiment|Positive

The call was predominantly positive, with management highlighting progress toward a potential first registrational study for Varseta-M in the first half of 2027, encouraging progression-free survival, improved Grade 3 diarrhea results in dose optimization, expanding combination and pan-tumor programs, continued CX-801 enrollment, and cash runway into the second half of 2028. These positives were tempered by lower revenue following the Astellas collaboration conclusion, higher operating expenses, ongoing gastrointestinal toxicity management, and the delay of the monotherapy update to January.

Company Guidance

CytomX expects to move Varseta-M monotherapy into a potential registrational study in the first half of 27, with an integrated update in January including the first look at overall survival, which is anticipated to be the primary endpoint in the initial registrational study; the bevacizumab combination is expected to report initial clinical data in the first half of 27, while the Varseta-M combination with bevacizumab, 5-fluorouracil and leucovorin is expected to start by the end of the year as a new Phase 1/2 trial, initially enrolling most likely late stage patients before the phase 2 part enrolls second line patients once phase 1 dose finding is successfully completed. CytomX has initiated gastrointestinal cohorts in unselected gastric and gastroesophageal junction cancer, EpCAM selected pancreatic ductal adenocarcinoma and EpCAM selected biliary tract cancer, with an initial plan to enroll approximately 20 patients per tumor type, and expects to report initial CX-801 melanoma data in the first half of 27. The company’s goal is to manage grade 3 diarrhea to 20% or below, and it projects cash runway into the second half of 28.

  • Varseta-M Advancing Toward First Registrational StudyCytomX is advancing Varseta-M toward its first potential registrational study in the first half of 2027. The company is initially developing the EpCAM-targeting topo-1 ADC in metastatic colorectal cancer, with the potential for a first approval and a meaningful market opportunity.
  • First-in-Class EpCAM-Targeting ADCManagement stated that Varseta-M is, to its knowledge, the first and only EpCAM-directed ADC in clinical development. The program is enabled by CytomX's PROBODY platform and is intended to provide differentiation and long-term value creation.
  • Significant Addressable Colorectal Cancer PopulationCytomX estimates approximately 35,000 addressable patients in the United States with third-line or later colorectal cancer. Management cited significant unmet need and limited clinical benefit from existing therapies in this population.
  • Encouraging Phase 1 Progression-Free SurvivalThe company previously reported encouraging progression-free survival at Varseta-M doses of 8.6 and 10 milligrams per kilogram, with results exceeding current standard of care. The Phase 1 study has enrolled more than 100 patients across dose-escalation, expansion, and optimization cohorts.
  • Dose Optimization and January Data UpdateCytomX is evaluating 8.6 and 10 milligrams per kilogram every three weeks using adjusted ideal body weight dosing and upfront prophylaxis to manage gastrointestinal adverse events. The company expects to provide an integrated update in January, including progression-free survival from the optimization cohorts and the first look at overall survival from the escalation and expansion cohorts.
  • Overall Survival Planned as Initial Registrational EndpointManagement stated that overall survival is expected to be the primary endpoint in Varseta-M's initial randomized registrational study. The company is evaluating third-line-plus development options and noted that treatment in this setting is fragmented.
  • Combination Development Expanding Into Earlier-Line DiseaseThe ongoing Phase 1 study of Varseta-M with bevacizumab continues to enroll late-line colorectal cancer patients, with initial clinical data anticipated in the first half of 2027. CytomX also remains on track to initiate a new Phase 1/2 study by the end of 2026 combining Varseta-M with bevacizumab, 5-fluorouracil, and leucovorin, with second-line patients planned for the Phase 2 portion after Phase 1 dose finding.
  • Strategy to Replace Irinotecan in Bev-Chemotherapy CombinationThe bevacizumab-chemotherapy combination strategy is designed to replace irinotecan with Varseta-M. Management stated that the topo-1 ADC was designed with this objective in mind and that the study will evaluate the combination's ability to work with the other agents.
  • Broader Pan-Tumor Development InitiatedCytomX has initiated Phase 1 cohorts in additional EpCAM-expressing gastrointestinal cancers: unselected gastric and gastroesophageal junction cancer, as well as EpCAM-selected pancreatic ductal adenocarcinoma and biliary tract cancer. The initial plan is to enroll approximately 20 patients per tumor type to evaluate antitumor activity and safety.
  • CX-801 Clinical Program ContinuesThe company continues to enroll the Phase 1 CX-801 study in checkpoint-refractory melanoma, evaluating CX-801 as monotherapy and in combination with KEYTRUDA. Monotherapy enrollment has exceeded dose levels of approved unmasked interferon alpha 2b, and initial biomarker data have reinforced the mechanism-of-action hypothesis for the combination. Initial clinical data are expected in the first half of 2027.
  • Improved Grade 3 Diarrhea Rate in Dose Optimization CohortsAfter two months of matched follow-up, the first 20 patients across the 8.6 and 10 milligrams per kilogram dose-optimization cohorts had a 10% rate of Grade 3 diarrhea, compared with more than 30% in time-matched patients from the escalation and expansion cohorts.
  • Defined Goal for Managing Gastrointestinal ToxicityManagement stated that the goal is to manage Grade 3 diarrhea to 20% or below, based on discussions with oncologists and market research. The company reported that Grade 3 diarrhea has a time to onset of approximately five weeks and does not appear to be cumulative.
  • Low Hematologic Toxicity HighlightedManagement described Varseta-M's rate of hematologic toxicity as remarkably low relative to other topo-1 ADCs in development in colorectal cancer and elsewhere, identifying this as a potentially attractive aspect of the safety profile.
  • Strong Liquidity and Extended Cash RunwayAs of September 30, 2026, CytomX had $348 million in cash, cash equivalents, and investments, compared with $330 million in cash as of June 30, 2026. The company projects cash runway into the second half of 2028, funding its stated Varseta-M registrational, combination, and gastrointestinal tumor priorities.
  • Regeneron Collaboration PaymentThe September 30, 2026 cash balance included $37 million received from Regeneron following its selection of two additional targets under the recently expanded collaboration.
  • Efficient and Flexible Operating StructureManagement stated that CytomX continues to maintain an efficient and flexible cost structure while broadening the Varseta-M development program. The company also said it will remain disciplined in capital allocation as it progresses the most compelling development priorities.

DE:6C1 Earnings History

DE:6C1 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 24, 20272026 (Q4)-0.07--0.16――
Nov 05, 20262026 (Q3)-0.06-0.08-0.080.00% (+0.00)
Aug 06, 20262026 (Q2)-0.07-0.080―
May 07, 20262026 (Q1)-0.11-0.090.24-137.04% (-0.33)
Mar 16, 20262025 (Q4)-0.08-0.160.2-178.64% (-0.35)
Nov 06, 20252025 (Q3)-0.04-0.080.06-228.57% (-0.14)
Aug 07, 20252025 (Q2)-0.060.00-0.07100.00% (+0.07)
May 12, 20252025 (Q1)0.110.240.1558.82% (+0.09)
Mar 06, 20252024 (Q4)-0.180.200.021000.00% (+0.18)
Nov 07, 20242024 (Q3)-0.160.060.0475.00% (+0.03)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed